eFFECTOR Therapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2020 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
eFFECTOR Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2020 to Q1 2024.
  • eFFECTOR Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending March 31, 2024 was -$8.83M, a 11.8% increase year-over-year.
  • eFFECTOR Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending March 31, 2024 was -$34.6M, a 3.13% increase year-over-year.
  • eFFECTOR Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$35.8M, a 58% decline from 2022.
  • eFFECTOR Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$22.7M, a 243% decline from 2021.
  • eFFECTOR Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was $15.8M, a 11.2% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$34.6M -$8.83M +$1.18M +11.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$35.8M -$9.13M +$130K +1.4% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-26
Q3 2023 -$35.9M -$8.3M +$1.26M +13.1% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-13
Q2 2023 -$37.2M -$8.36M -$1.45M -21% Apr 1, 2023 Jun 30, 2023 10-Q 2023-11-13
Q1 2023 -$35.7M -$10M -$13.1M -426% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$22.7M -$9.26M -$28.3M -149% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-26
Q3 2022 $5.64M -$9.56M -$18.4M -208% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 $24.1M -$6.92M -$1.37M -24.6% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-13
Q1 2022 $25.4M $3.07M +$9.65M Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-13
Q4 2021 $15.8M $19M +$24.9M Oct 1, 2021 Dec 31, 2021 10-K 2023-03-08
Q3 2021 -$9.11M $8.88M +$16.5M Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 -$25.6M -$5.55M -$14.1M -165% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-07
Q1 2021 -$11.5M -$6.58M -$25.7M -134% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-07
Q4 2020 $14.2M -$5.85M Oct 1, 2020 Dec 31, 2020 10-Q 2021-11-08
Q3 2020 -$7.61M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 $8.59M Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-08
Q1 2020 $19.1M Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.